Nasonex (Mometasone Furoate)

Mometasone furoate is a synthetic glucocorticoid that binds to glucocorticoid receptors in nasal mucosal cells. This binding suppresses cytokine production, limits inflammatory cell infiltration, and stabilises cell membranes, thereby decreasing swelling and mucus formation in the nose.

The specific dose and frequency of Nasonex are determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions and the product’s label.

Nasonex is classified as Pregnancy Category C, meaning risk cannot be ruled out. It should be used only if the potential benefit justifies the potential risk to the fetus. While limited data exist for breastfeeding, it is recommended to use the medication only when clearly needed and after consulting a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasonex (mometasone furoate) is a high‑potency intranasal corticosteroid with a favorable safety profile when used as directed. Compared with agents such as fluticasone or budesonide, mometasone offers similar anti‑inflammatory efficacy but may have a slightly lower systemic absorption, reducing the risk of systemic side effects.

Store Nasonex at room temperature, below 25 °C (77 °F). Keep the spray in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

Nasonex is delivered as a metered‑dose nasal spray. The patient should gently blow the nose, insert the tip into one nostril, close the opposite nostril, and spray while breathing in gently. The recommended number of sprays per nostril is set by the prescriber.

Serious risks, though rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal cavity. Patients should seek immediate medical attention if they experience unusual bleeding, severe pain, or signs of systemic infection.

Nasonex should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery or trauma, and those who have experienced severe adverse reactions to other intranasal corticosteroids.